|
[1] VERNON G, BARANOVA A, YOUNOSSI ZM. Systematic review:The epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults[J]. Aliment Pharmacol Ther, 2011, 34 (3) :274-285.
|
|
[2] DAS K, DAS K, MUKHERJEE PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease[J]. Hepatology, 2010, 51 (5) :1593-1602.
|
|
[3] EVERHART JE, BAMBHA KM. Fatty liver:Think globally[J]. Hepatology, 2010, 51 (5) :1491-1493.
|
|
[4] FABBRINI E, SULLIVAN S, KLEIN S. Obesity and nonalcoholic fatty liver disease:Biochemical, metabolic, and clinical implications[J]. Hepatology, 2010, 51 (2) :679-689.
|
|
[5] TARGHER G, DAY CP, BONORA E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363 (14) :1341-1350.
|
|
[6] HAMAGUCHI M, KOJIMA T, TAKEDA N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease[J].Ann Intern Med, 2005, 143 (10) :722-728.
|
|
[7] ROTMAN Y, SANYAL AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J]. Gut, 2017, 66 (1) :180-190.
|
|
[8] YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al. Pathologic criteria for nonalcoholic steatohepatitis:Interprotocol agreement. and ability to predict liver-related mortality[J]. Hepatology, 2011, 53 (6) :1874-1882.
|
|
[9] MAO YM. Clinical trials of investigational new drugs for nonalcoholic steatohepatitis:Challenges in design and practice[J]. J Clin Hepatol, 2017, 33 (12) :2292-2295. (in Chinese) 茅益民.非酒精精性脂肪性肝炎新药临床试验:设计和实践中的挑战[J].临床肝胆病杂志, 2017, 33 (12) :2292-2295.
|
|
[10] SANYAL AJ, FRIEDMAN SL, MCCULLOUGH AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an american association for the Study of Liver Diseases–U. S. Food and Drug Administration Joint Workshop[J]. Hepatology, 2015, 61 (4) :1392-1405.
|
|
[11] LOOMBA R. Role of imaging-based biomarkers in NAFLD:Recent advances in clinical application and future research directions[J]. J Hepatol, 2018, 68 (2) :296-304.
|
|
[12] VILAR-GOMEZ E, CHALASANI N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J]. J Hepatol, 2018, 68 (2) :305-315.
|
DownLoad: